Mesoblast LtdNASDAQ:MESO
- LAST PRICE9.7350
- TODAY'S CHANGE (%)0.5550 (6.0458%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close9.6700 / 9.1800
- Day Range
- 52 Week Range
- Volume146,330
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MESO |
|---|---|---|
| 09:32 ET | 5405 | 9.675 |
| 09:33 ET | 5052 | 9.7774 |
| 09:35 ET | 715 | 9.7499 |
| 09:37 ET | 250 | 9.53 |
| 09:39 ET | 1215 | 9.692 |
| 09:42 ET | 300 | 9.61 |
| 09:44 ET | 100 | 9.64 |
| 09:46 ET | 100 | 9.575 |
| 09:50 ET | 842 | 9.575 |
| 09:51 ET | 300 | 9.575 |
| 09:53 ET | 300 | 9.6307 |
| 09:55 ET | 159 | 9.5372 |
| 09:57 ET | 2131 | 9.54 |
| 10:02 ET | 100 | 9.6199 |
| 10:04 ET | 2239 | 9.7 |
| 10:06 ET | 545 | 9.69 |
| 10:08 ET | 300 | 9.57 |
| 10:09 ET | 1272 | 9.57 |
| 10:20 ET | 500 | 9.58 |
| 10:22 ET | 100 | 9.585 |
| 10:26 ET | 3906 | 9.5 |
| 10:27 ET | 387 | 9.3613 |
| 10:33 ET | 159 | 9.58 |
| 10:40 ET | 400 | 9.57 |
| 10:42 ET | 600 | 9.5708 |
| 10:44 ET | 600 | 9.57 |
| 10:49 ET | 500 | 9.475 |
| 10:51 ET | 100 | 9.48 |
| 11:05 ET | 100 | 9.4615 |
| 11:07 ET | 179 | 9.5675 |
| 11:12 ET | 116 | 9.6899 |
| 11:14 ET | 204 | 9.55 |
| 11:18 ET | 100 | 9.545 |
| 11:23 ET | 902 | 9.6 |
| 11:34 ET | 900 | 9.5799 |
| 11:48 ET | 400 | 9.548472 |
| 11:50 ET | 300 | 9.52 |
| 11:57 ET | 299 | 9.5 |
| 11:59 ET | 300 | 9.48 |
| 12:01 ET | 200 | 9.53 |
| 12:14 ET | 15840 | 9.6194 |
| 12:15 ET | 14049 | 9.7199 |
| 12:24 ET | 576 | 9.7799 |
| 12:26 ET | 100 | 9.74 |
| 12:28 ET | 682 | 9.737 |
| 12:44 ET | 139 | 9.73 |
| 12:51 ET | 121 | 9.73 |
| 01:02 ET | 375 | 9.7 |
| 01:04 ET | 888 | 9.745 |
| 01:06 ET | 3154 | 9.66 |
| 01:08 ET | 1846 | 9.7 |
| 01:11 ET | 300 | 9.67 |
| 01:13 ET | 415 | 9.6981 |
| 01:22 ET | 5115 | 9.67 |
| 01:24 ET | 16332 | 9.68 |
| 01:33 ET | 5159 | 9.64 |
| 01:36 ET | 234 | 9.61 |
| 02:05 ET | 1028 | 9.65 |
| 02:14 ET | 150 | 9.6599 |
| 02:18 ET | 1641 | 9.71 |
| 02:20 ET | 612 | 9.68 |
| 02:21 ET | 200 | 9.71 |
| 02:25 ET | 1000 | 9.7022 |
| 02:30 ET | 100 | 9.7499 |
| 02:41 ET | 1526 | 9.72 |
| 02:43 ET | 400 | 9.75 |
| 02:50 ET | 293 | 9.7348 |
| 02:52 ET | 384 | 9.69 |
| 02:54 ET | 300 | 9.73 |
| 02:59 ET | 2104 | 9.76 |
| 03:01 ET | 380 | 9.76 |
| 03:06 ET | 1107 | 9.775 |
| 03:08 ET | 1275 | 9.73 |
| 03:12 ET | 150 | 9.7201 |
| 03:17 ET | 1051 | 9.74 |
| 03:28 ET | 601 | 9.725 |
| 03:30 ET | 114 | 9.7101 |
| 03:32 ET | 100 | 9.71 |
| 03:33 ET | 100 | 9.7 |
| 03:35 ET | 556 | 9.72 |
| 03:37 ET | 210 | 9.72 |
| 03:42 ET | 500 | 9.7 |
| 03:44 ET | 466 | 9.69 |
| 03:46 ET | 100 | 9.69 |
| 03:48 ET | 600 | 9.695 |
| 03:50 ET | 100 | 9.68 |
| 03:51 ET | 673 | 9.7 |
| 03:53 ET | 100 | 9.67 |
| 03:55 ET | 100 | 9.69 |
| 03:57 ET | 100 | 9.7 |
| 04:00 ET | 5378 | 9.735 |
Oct 30, 2024
Press Release: Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024, from 7:11PM ET on Wednesday Oct 30, 2024 by Dow Jones
7:11PM ET on Wednesday Oct 30, 2024 by Dow JonesAppendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024, from 7:11PM ET on Wednesday Oct 30, 2024 by Dow Jones
7:11PM ET on Wednesday Oct 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mesoblast Ltd | 1.1B | -11.1x | --- |
Septerna Inc | 1.1B | -101,840.0x | --- |
89Bio Inc | 1.1B | -3.5x | --- |
Cogent Biosciences Inc | 1.1B | -4.2x | --- |
Arrivent Biopharma Inc | 1.2B | -13.9x | --- |
Applied Therapeutics Inc | 1.2B | -6.7x | --- |
Company Information
Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.
Contact Information
- Headquarters
- L 38 55 Collins StMELBOURNE, VIC, Australia 3000
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- Jane Bell
- Chief Executive Officer, Executive Director
- Silviu Itescu
- Non-Executive Independent Vice Chairman of the Board
- William Burns
- Interim Chief Financial Officer
- Andrew Chaponnel
- Senior Vice President, Head - Translational Research
- Fiona See
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.1B |
|---|---|
Revenue (TTM) | $5.9M |
Shares Outstanding | 114.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 3.49 |
EPS | $-0.88 |
Book Value | $4.21 |
P/E Ratio | -11.1x |
Price/Sales (TTM) | 185.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,173.11% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
